*Articles from the former Asklep
Asklep Inc. (Headquarters: 3-1-3 Higashi Ikebukuro, Toshima-ku, Tokyo, Japan, Representative Director and President: Hiroshi Ichikawa) establishes “ASKLEP KOREA Inc.” in November 2012 to expand its drug development contract research organization (CRO) business.
Along with the globalization of the drug development, we have been expanding overseas business through the establishment of subsidiaries in China (ASKLEP CHINA Inc.) and Taiwan (ASKLEP TAIWAN Inc.), while forming strategic partnerships with global CROs in Europe, USA, and Asia.
By establishing a subsidiary in Korea that has a growth in both global and local clinical studies, our aim is to develop strong local network for responding the needs of our clients and to increase the number of contracts for conducting clinical trials in East Asia.
About ASKLEP Korea
|Company name :||ASKLEP KOREA Inc.|
|Headquarters :||Seoul, South Korea|
|Capital :||200 million Korean won (ASKLEP: 100%)|
|Representative director :||Hiroshi Ichikawa|
|To Be Established :||November 2012|
|Services :||Monitoring , Data Management / Biostatistics , Consulting|